February 9, 2019

FDA Nudges Developers to Create Over-the-Counter Naloxone

The FDA announced an initiative to encourage drug companies to develop over-the-counter (OTC) formulations of naloxone, the opioid overdose reversal agent, in order to improve consumer access to the drug and reduce opioid-related fatalities.

A key step to being granted FDA approval on an OTC drug is the development of a consumer-friendly drug facts label (DFL) alongside studies demonstrating that consumers can understand how to use the product without the supervision of a healthcare professional.

Many have claimed this process to be a barrier to development. To spur OTC development, for the very first time the FDA has proactively developed and tested DFLs for an OTC product, releasing model DFLs for naloxone auto-injectors and nasal sprays.

Going a step further, the FDA also conducted the necessary label comprehension testing, establishing that these DFLs are consumer friendly and essentially clearing a primary hurdle for drug developers, allowing drug makers to insert product-specific information into their labels and focus on product development.

It is very likely that this will lead to the creation of OTC naloxone products, as naloxone has seen a variety of legislative and regulatory actions over the last several years, expanding access to this life-saving drug. In fact, in certain states, select pharmacies sell naloxone without a prescription. However, as an OTC, the utilization of naloxone may go unnoticed in workers’ comp, whereas its mere presence in a claim could serve as a helpful red flag to spot issues with opioid utilization.

For more information, read the FDA’s press announcement.

Workers’ Comprehensive

News and views in workers’ comp

Important news in workers’ comp delivered to your inbox